Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nell-like molecule 1 (NELL-1)
- Target
- NELL-1
- Molecular classification
- Secreted signaling molecule, Extracellular matrix-associated protein, Multi-domain protein: contains EGF-like, von Willebrand factor C-like, thrombospondin-type N-terminal domains
01
Overview
Nell-like molecule 1 (NELL-1) is a secreted, multimodular protein characterized by EGF-like, von Willebrand factor C-like, and thrombospondin-type N-terminal domains[2][1][4]. NELL-1 plays a pivotal role in promoting osteoblast differentiation, bone formation, and skeletal development by binding to integrin α3β1 and activating the Wnt/β-catenin pathway[2][3]. It is also involved in cell adhesion, extracellular matrix interactions, neural development, and angiogenesis[1][2][5]. While recombinant NELL-1 is being studied as a biologic therapeutic agent for osteoporosis and bone regeneration, there is no recognized "Nell-like molecule 1 receptor" in human physiology. The term "Nell-like molecule 1 receptor" is therefore considered incorrect or misleading in current scientific contexts.
- Other names
- NELL1NELL-1 proteinNel-like protein 1
02
Mechanism of action
NELL-1 binds to integrins (notably integrin α3β1 and β1) Activates Wnt/β-catenin signaling pathways Interacts with heparan sulfate proteoglycans and extracellular matrix molecules
03
Biological functions
Regulation of osteogenesis and chondrogenesis (bone and cartilage formation)Promotion of osteoblast differentiation and mineralizationRegulation of cell adhesionModulation of angiogenesisNeural development
04
Disease associations
Skeletal disorders (osteoporosis, craniosynostosis, bone developmental defects)Possible roles in cancer and tissue regeneration (suggested but not fully established)Dental and orofacial tissue regeneration
05
Safety considerations
High or dysregulated NELL-1 expression may contribute to craniosynostosis and abnormal bone growthSystemic delivery in animal models is still being evaluated for adverse effects
06
Interacting drugs
None established or clinically validated; recombinant NELL-1 protein is being investigated as a potential therapeutic agent
07
Biomarkers
No clinically validated biomarkers for NELL-1-based therapy or patient selection; NELL-1 expression may be investigated as a marker of osteogenic capacity in research contexts
Beyond the preview
Go deeper on Nell-like molecule 1 (NELL-1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nell-like molecule 1 (NELL-1).